다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland, v.13 no.5, 2015년, pp.271 - 278
Zeidan, B.A. , Townsend, P.A. , Garbis, S.D. , Copson, E. , Cutress, R.I.
AI-Helper
Background: Breast cancer is a heterogeneous disease. Yet, many molecular players and mechanisms behind the complexity of its clinical behaviour remain unknown, and advances in biomedical research are expected to unravel novel molecular discoveries in breast and other cancers. Clinical proteomics is...
Cancer Research UK. Cancer statistics report: cancer incidence and mortality in the UK., vol. 2013, 2013.
CA Cancer J Clin Jemal 60 277 2010 10.3322/caac.20073 Cancer statistics, 2010
CA Cancer J Clin Siegel 62 10 2012 10.3322/caac.20138 Cancer statistics, 2012
Ann Oncol Off J Eur Soc Med Oncol/ESMO Boyle 16 481 2005 10.1093/annonc/mdi098 Cancer incidence and mortality in Europe, 2004
Arch Gynecol Obstet Varga 282 427 2010 10.1007/s00404-009-1339-y Comparison of early onset breast cancer patients to older premenopausal breast cancer patients
Breast Cancer Res Treat Lawrence 116 179 2009 10.1007/s10549-008-0100-8 Population estimates of survival in women with screen-detected and symptomatic breast cancer taking account of lead time and length bias
Nat Rev Cancer Ludwig 5 845 2005 10.1038/nrc1739 Biomarkers in cancer staging, prognosis and treatment selection
Nature Sawyers 452 548 2008 10.1038/nature06913 The cancer biomarker problem
Breast Cancer Res BCR Zeidan 10 107 2008 10.1186/bcr2107 SELDI-TOF proteomic profiling of breast carcinomas identifies clinicopathologically relevant groups of patients similar to previously defined clusters from cDNA expression
Nature Curtis 486 346 2012 10.1038/nature10983 The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
Nat Med Vogelstein 10 789 2004 10.1038/nm1087 Cancer genes and the pathways they control
Clin Nutr McCoy 32 728 2013 10.1016/j.clnu.2012.12.015 The 2010 ESPEN Sir David Cuthbertson Lecture: new and old proteins: clinical implications
Cancer Genomics Proteomics Zeidan 6 141 2009 Proteomic analysis of archival breast cancer serum
Dis Markers Laronga 19 229 2003 10.1155/2004/759530 SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers
Clin Chem Li 48 1296 2002 10.1093/clinchem/48.8.1296 Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer
Clin Chem Li 51 2229 2005 10.1373/clinchem.2005.052878 Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry
J Clin Invest Villanueva 116 271 2006 10.1172/JCI26022 Differential exoprotease activities confer tumor-specific serum peptidome patterns
Cancer Pusztai 100 1814 2004 10.1002/cncr.20203 Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma
Breast Cancer Res Treat Pawlik 89 149 2005 10.1007/s10549-004-1710-4 Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry
Ann Surg Oncol Becker 11 907 2004 10.1245/ASO.2004.03.557 Surfaced-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) differentiation of serum protein profiles of BRCA-1 and sporadic breast cancer
Proc Natl Acad Sci U S A Sorlie 98 10869 2001 10.1073/pnas.191367098 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
Breast Cancer Res BCR Brozkova 10 R48 2008 10.1186/bcr2101 Surface-enhanced laser desorption/ionization time-of-flight proteomic profiling of breast carcinomas identifies clinicopathologically relevant groups of patients similar to previously defined clusters from cDNA expression
Breast Cancer Res BCR Katchman 15 R28 2013 10.1186/bcr3407 Expression of quiescin sulfhydryl oxidase 1 is associated with a highly invasive phenotype and correlates with a poor prognosis in Luminal B breast cancer
PLoS One Cawthorn 7 e30992 2012 10.1371/journal.pone.0030992 Proteomic analyses reveal high expression of decorin and endoplasmin (HSP90B1) are associated with breast cancer metastasis and decreased survival
Cancer Res Duffy 48 1348 1988 Tissue-type plasminogen activator, a new prognostic marker in breast cancer
Int J Oncol Descotes 41 92 2012 Identification of potential prognostic biomarkers for node-negative breast tumours by proteomic analysis: a multicentric 2004 national PHRC study
PLoS One He 8 e75366 2013 10.1371/journal.pone.0075366 Serum soluble CD14 is a potential prognostic indicator of recurrence of human breast invasive ductal carcinoma with Her2-enriched subtype
Nat Commun Johansson 4 2175 2013 10.1038/ncomms3175 Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer
Cytom Part A J Int Soc Anal Cytol Apweiler 75 816 2009 10.1002/cyto.a.20779 Approaching clinical proteomics: current state and future fields of application in cellular proteomics
Clin Proteomics Fuzery 10 13 2013 10.1186/1559-0275-10-13 Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges
Eur J Cancer Harbeck 49 1825 2013 10.1016/j.ejca.2013.01.007 Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.